HighPoint Advisor Group’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

HighPoint Advisor Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,132	Closed	-$426K	–	706
2026 Q1	$426K	Sell	14,132 -16,308	-54%	-$525K	0.02%	454
2025 Q4	$950K	Buy	+30,440	New	+$750K	0.02%	481
2021 Q3	$98K	Buy	+10,056	New	+$94.2K	0.01%	535
2019 Q3	–	Sell	-12,356	Closed	-$95K	–	517
2019 Q2	$95K	Sell	12,356 -564	-4%	-$6.8K	0.02%	471
2019 Q1	$188K	Buy	12,920 +1,035	+9%	+$18.3K	0.05%	314
2018 Q4	$214K	Buy	11,885 +1,153	+11%	+$23.6K	0.06%	280
2018 Q3	$228K	Buy	+10,732	New	+$249K	0.06%	276
2017 Q1	–	Sell	-6,250	Closed	-$219K	–	301
2016 Q4	$219K	Buy	6,250 +1,010	+19%	+$40.3K	0.07%	254
2016 Q3	$204K	Buy	5,240 +916	+21%	+$47.8K	0.07%	256
2016 Q2	$231K	Buy	+4,324	New	+$230K	0.08%	238

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

HighPoint Advisor Group's TEVA Position: Q2 2026 in Review

HighPoint Advisor Group sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2026, closing a stake of 14,132 shares — an estimated $426K sold.

HighPoint Advisor Group first reported a position in TEVA in Q2 2016 and held it in 10 quarters. The position peaked at $950K in Q4 2025. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

HighPoint Advisor Group reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2026 after selling out during the quarter.
HighPoint Advisor Group sold 14,132 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $426K.
HighPoint Advisor Group first reported a position in Teva Pharmaceutical Industries Limited in Q2 2016 and held it in 10 quarters.
HighPoint Advisor Group's Teva Pharmaceutical Industries Limited position peaked at $950K in Q4 2025.
676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on HighPoint Advisor Group's 13F filing for Q2 2026, filed 5 Aug 2026.